ClinicalTrials.gg
RecruitingNCT07198555Updated Nov 18, 2025

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis.

A Phase 1 interventional study of BBM-A101 and Placebo in Knee Osteoarthritis, sponsored by Belief BioMed (Beijing) Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Belief BioMed (Beijing) Co., Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.

Planned enrollment
66th of 115
81 · median 100
Started
2025
with 9 others
Phase 1
10 of 136
6 open now
Primary completion
2027-12
later than 28 of 31 live
Registered
123rd of 136
by date

Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 66th largest by planned enrollment of the 115 interventional ones that give a count, is one of 10 that started in 2025, is one of 10 in phase 1, reaches primary completion later than 28 of the 31 other live ones, and was the 123rd registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis, Knee with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-A101 to treat participants with knee osteoarthritis.

Read the detailed description

This study is divided into two phases: Phase Ia and Phase Ib . Phase Ia is a randomized, single-blind study . Phase Ib is a randomized, double blind, parallel assignment study.

BBM-A101 is an AAVbased gene therapy that delivers a therapeutic gene cassette into knee for the treatment of knee osteoarthritis.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • knee osteoarthritis
  • gene therapy
  • Adeno-Associated Virus
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with moderate knee osteoarthritis .
  2. The knee joint was evaluated as having Kellgren-Lawrence grade 2 or 3.
  3. The (BMI) ranges from 18.0 to 35.0 kg/m2 (including the boundary values).
  4. Lower titers of antibodies binding to the BBM-A101 capsid in the blood.
  5. Participants who had received adequate treatment with conventional medications previously, experienced recurrence or aggravation of target knee arthritis after discontinuation of medication, and still had moderate pain; during the screening period, the WOMAC pain score of the target knee was ≥ 8 .
  6. From the time of screening to 52 weeks after dosing , the participants had no intention of having children and voluntarily took effective measures, and there were no plans for sperm donation or ova donation.
  7. Voluntarily sign the form and be able to complete the research as required by the clinical trial protocol.

    -

Exclusion criteria

Exclusion Criteria:

  1. There is a possibility of secondary knee osteoarthritis, or the knee joint symptoms may not be caused by knee osteoarthritis, or there may be other medical histories of diseases that other researchers believe could potentially lead to knee osteoarthritic inflammation.
  2. History of lumbar dischernaiation, accompanied by lower limb nerve symptoms that may affect the assessment of the study.
  3. Participants who are unable or unwilling to undergo MRI examination, or who have to MRI.
  4. Participants who are unable or unwilling to undergo joint fluid extraction.
  5. During the screening period and before dosing, there were abnormal values in the laboratory tests, and the researchers believed that these might pose risks to the participants in the clinical trial.
  6. Those with positive results for virus surface antigen or hepatitis B virus deoxyribonucleic acid or virus ribonucleic acid test or antibody or Treponema pallidum antibody.
  7. Currently undergoing treatment for hepatitis B and hepatitis C.
  8. Participants who had persistent chronic or active infections within the previous 4 weeks were selected.
  9. Participants who had coagulation disorders (such as hemophilia) or existing medical conditions that require anticoagulation therapy and make knee joint injection impossible.
  10. Having or having had cancer or malignant tumors
  11. Having received genetic therapy or stem cell therapy before screening or having plans for genetic therapy or stem cell therapy during the study period.
  12. Any history of vaccination within 30 days prior to dosing or any vaccination schedule within 30 days after dosing.
  13. Screening will be conducted on female participants who are pregnant or breastfeeding or whose HCG test result is positive; or who have plans to get pregnant within the next 52 w.
  14. History of alcohol addiction or drug dependence, or inability to limit alcohol consumption during the research process.
  15. Participants had any mental disorders that might affect the assessment of the study.
  16. Having other conditions that the investigator consider unsuitable for participation in the study.

    -

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
81 participants (estimated)

Study arms

  • Placebo comparator
    Arm of Placebo

    Drug: Placebo

  • Experimental
    Arm of BBM-A101

    Drug: BBM-A101

Interventions

  • DrugBBM-A101

    Single-dose intra-articular (IA)injection (2ml)(phase Ia) Low dose group, Middle dose group; High dose group; Control group :Placebo

  • DrugPlacebo

    Placebo(phase Ia)

  • DrugBBM-A101

    Single-dose intra-articular (IA)injection (2ml)(phase Ib) Low dose group, High dose group Control group :Placebo

  • DrugPlacebo

    Placebo(phase Ib)

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT) events

    Time frame: within 4 weeks

  2. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To evaluate the safety of BBM-A101 by AEs and SAEs.

    Time frame: within 52 weeks

Secondary outcomes

  1. The protein levels of gene expression products in blood and joint fluid

    Time frame: within5 years

  2. The shedding of recombinant adeno-associated virus (rAAV) vectors in peripheral blood, joint fluid, urine, feces, saliva, and semen

    Time frame: within 5 years

  3. The change in the joint space width as detected by X-ray of the knee joint compared to the baseline

    Time frame: within 5 years

  4. The changes in the titers of AAV capsid-binding antibodies in the blood and joint fluid compared to the baseline level

    Time frame: within 5 years

  5. The changes in the titers of antibodies binding to the expressed products in the blood and joint fluid compared to the baseline level

    Time frame: within 5 years

07

Study locations

2 of 2 sites recruiting
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518035, China
    Recruiting
  • The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200011, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's planned 26 months is above that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Sep 30, 2025
StartActual
Oct 9, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2031
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07198555
Lead sponsor
Belief BioMed (Beijing) Co., Ltd
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Oct 9, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Nov 18, 2025

Study contacts

Wenshu Luo, Ph.D
Contact
luowenshu@beliefbiomed.com
021-33588288
Jie Zhao
principal investigator · The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion